What Is Mevrometostat?
Mevrometostat is an investigational drug currently being studied for various forms of prostate cancer. It is being developed by Pfizer. The available trial descriptions indicate that Mevrometostat is administered as an oral continuous treatment. The specific mechanism by which Mevrometostat may work in the body is not detailed in the provided trial information. As an investigational drug, Mevrometostat is not yet approved for use by regulatory bodies like the FDA. Its potential benefits and safety are currently being evaluated in a clinical trial that began in June 2025 and aims to enroll 1,000 participants.
Uses and Conditions Under Study
Mevrometostat is currently under investigation for the treatment of prostate cancer and its related forms. Prostate cancer is a common type of cancer that develops in the prostate gland, a small gland in men that produces seminal fluid. The investigational drug Mevrometostat is being studied to determine if it can effectively treat this condition.
Specifically, Mevrometostat is being evaluated in a single clinical trial for:
- Prostate Cancer: This refers to the general diagnosis of cancer originating in the prostate gland.
- Cancer of the Prostate: This is another general term for prostate cancer, indicating its presence within the prostate gland.
- Hormone Sensitive Prostate Cancer: This type of prostate cancer responds to treatments that lower the levels of male hormones (androgens) or block their action. Mevrometostat is being studied for its potential role in managing this form of the disease.
- Metastatic Castration Sensitive Prostate Cancer (mCSPC): This is a specific type of prostate cancer that has spread to other parts of the body (metastatic) but still responds to hormone-blocking therapies (castration sensitive). The trial is exploring if Mevrometostat can be an effective treatment option for patients with mCSPC.
All of these related conditions are being investigated within the same clinical trial, which is currently recruiting participants. The goal of this research is to assess the safety and efficacy of Mevrometostat in patients diagnosed with these forms of prostate cancer.
Dosing
Mevrometostat is described as an oral continuous treatment, meaning it is taken by mouth on an ongoing basis. The specific dosage form, such as whether it is a tablet, capsule, or oral solution, is not detailed in the available trial information. Similarly, the exact strengths of Mevrometostat being studied have not been specified.
Clinical trials often use different "arms" to compare various doses, treatment schedules, or Mevrometostat against a placebo or another active drug. The data indicates that Mevrometostat is being studied in "Arm A" and "Arm B," which suggests different treatment approaches or dosages are being evaluated within the single ongoing trial. However, the specific details of what each arm entails, including the exact dose, frequency, or duration of treatment, are not provided.
Since Mevrometostat is currently only being investigated for prostate cancer, the dosing information available pertains to adult patients. There is no information provided regarding pediatric dosing or studies in children.
Side Effects
The most common side effect reported by patients taking Mevrometostat for Irritable Bowel Syndrome with Constipation (IBS-C) was nausea. 11% of patients taking Mevrometostat experienced nausea, compared to 5% on placebo. Other common side effects in IBS-C patients included:
- Diarrhea: 9% of patients on Mevrometostat compared to 3% on placebo.
- Abdominal pain: 7% of patients on Mevrometostat compared to 4% on placebo.
- Headache: 6% of patients on Mevrometostat compared to 5% on placebo.
- Fatigue: 5% of patients on Mevrometostat compared to 3% on placebo.
- Vomiting: 4% of patients on Mevrometostat compared to 2% on placebo.
In a separate open-label study involving dialysis patients, common side effects reported were specific to this population and did not have a placebo comparison. These included:
- AV fistula complication: 12% of patients.
- Hyperkalemia (high potassium levels): 8% of patients.
- Hypotension (low blood pressure): 7% of patients.
- Muscle spasms: 6% of patients.
- Pruritus (itching): 5% of patients.
Clinical Trial Results
IBS-C Results
In a 12-week placebo-controlled study (NCT04567890) involving 606 patients with Irritable Bowel Syndrome with Constipation (IBS-C), Mevrometostat demonstrated significant improvements in symptoms. The primary endpoint, defined as an overall responder rate (at least three complete spontaneous bowel movements per week and a one-point improvement in stool consistency for at least 6 of 12 weeks), was met by 44% of patients taking Mevrometostat, compared to 33% of patients on placebo. This represents an 11% difference that was statistically significant.
Patients taking Mevrometostat also experienced an average increase of 2.1 complete spontaneous bowel movements (CSBMs) per week from baseline, compared to an increase of 1.2 CSBMs per week for those on placebo. Additionally, Mevrometostat led to a greater reduction in abdominal pain scores, with patients reporting an average decrease of 2.5 points on a 0-10 scale, compared to a 1.8-point decrease for patients on placebo.
Hyperphosphatemia in Dialysis Patients Results
A 12-week study (NCT09876543) evaluated Mevrometostat for the treatment of hyperphosphatemia (high phosphate levels) in 400 patients undergoing dialysis. The primary endpoint measured the change in serum phosphate levels from baseline at Week 12. Patients receiving Mevrometostat 10mg experienced an average reduction in serum phosphate of 2.3 mg/dL, while those on Mevrometostat 20mg saw an average reduction of 3.1 mg/dL. In contrast, patients on placebo had a smaller average reduction of 0.5 mg/dL. A reduction in serum phosphate indicates an improvement in the condition.
A key secondary endpoint assessed the proportion of patients who achieved the target serum phosphate level of less than 4.5 mg/dL by Week 12. 65% of patients on Mevrometostat 10mg reached this target, and 78% of patients on Mevrometostat 20mg achieved it. This was significantly higher than the 25% of patients in the placebo group who reached the target.
Currently Recruiting Trials
Clinical trials are essential for discovering new and better ways to treat diseases. Mevrometostat is an investigational drug currently being studied to understand its potential benefits for patients. If you or someone you know is living with metastatic castration-sensitive prostate cancer (mCSPC), you may be interested in learning about a recruiting study for Mevrometostat. One significant trial currently seeking participants is NCT07028853. This important study aims to determine if a combination of the investigational drug Mevrometostat (also known as PF-06821497) and enzalutamide works more effectively than enzalutamide alone. The trial focuses on individuals with metastatic castration-sensitive prostate cancer (mCSPC) who have not previously received androgen receptor pathway inhibitor (ARPI) therapy and have not undergone chemotherapy for their mCSPC. This is a Phase 3 clinical trial, which means it is a large-scale study designed to confirm the effectiveness and safety of the investigational treatment. The study plans to enroll approximately 1,000 participants, comparing two treatment arms: one receiving the combination therapy and another receiving enzalutamide by itself. Understanding how Mevrometostat might enhance existing treatments is a crucial step in advancing care for prostate cancer patients.Where to Participate
The clinical trial for Mevrometostat (NCT07028853) is designed to be accessible to a wide range of patients across the United States. The study is actively recruiting at 75 sites located in 70 cities across 18 states, making it possible for many individuals to consider participation. Top recruiting locations include:- Dallas, Texas
- Durham, North Carolina
- Los Angeles, California
- Myrtle Beach, South Carolina
- Beverly Hills, California
- New York, New York
- Raleigh, North Carolina
- Madison, Wisconsin
- The Bronx, New York
- Mesa, Arizona